已发表论文

对艾滋病患者接受 HAART 治疗的成本效益分析的叙述性综述: 从干预措施到成果

 

Authors Tse WF, Yang W, Huang W
Received 26 March 2015
Accepted for publication 4 June 2015
Published 11 August 2015 Volume 2015:7 Pages 431—439
DOI http://dx.doi.org/10.2147/CEOR.S85535
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication:  Professor Giorgio Colombo

Background: Since its introduction in 1996, highly active antiretroviral therapy (HAART), which involves the combination of antiretroviral drugs, has resulted in significant improvements in the morbidity, mortality, and life expectancy of HIV-infected patients. Numerous studies of the cost-effectiveness of HAART from different perspectives in HIV have been reported.
Aim: To investigate the economic outcomes and relevance of HAART for people living with HIV.
Materials and methods: A narrative literature review was conducted on 22 peer-reviewed full economic evaluations of people living with HIV treated with different HAART regimens and published in English between January 2005 and December 2014. Information regarding study details, such as interventions, outcomes, and modeling methods, was extracted. The high heterogeneity of the included studies rendered a meta-analysis inappropriate; therefore, we conducted a comparative analysis of studies grouped according to the similarity of the different intervention types and outcomes.
Results: Most of the economic evaluations of HAART focused on comparisons between the specific HAART regimens and others from the following perspectives: injecting drug users versus noninjecting drug users, HIV-infected adults without AIDS versus those with AIDS, regimens based on developed world guidelines versus those based on developing world guidelines, self-administered HAART versus directly observed HAART, and “ideal” versus “typical” regimens.
Conclusion: In general, HAART is more cost-effective than other therapeutic regimens adopted so far. Further investigations, especially head-to-head comparisons of “ideal” and “typical” trials of different regimen combinations, are required to identify the optimal HAART regimens.
Keywords: narrative review, cost-effectiveness, HAART